The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.
Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.
© 2020 DH Tech. Dev. Pte. Ltd.

Shaping the Next Generation of Proteomics and Quantitative Biology

Increase identifiable and quantifiable peptides

Register

Triple quadrupole mass spectrometer is the LC/MS platform of choice in bioanalysis of peptide or protein therapeutics, in which quantitation is usually accomplished by MRM detection of intact peptide or signature peptides of a targeted protein via enzymatic digestion. In some cases however peptides do not generate useful fragment ion(s) allowing for sensitive or selective MRM analysis. HRMS-based accurate analysis has been recently employed to solve this problem. In this presentation, we describe an alternative to HRMS by combining differential mobility spectrometry (DMS) and triple quadrupole-based multiple ion monitoring (MIM) for quantitation of peptides that cannot be effectively analyzed by MRM. Preliminary results suggest that the DMS-MIM workflow had assay LLOQ sensitivity and selectivity similar to HRMS results. This strategy enabled triple quadrupole MS instruments to perform the bioanalysis of poorly fragmented peptides. In addition, a workflow using DMS to reduce interference in peptide analysis by MRM is presented. Such orthogonal methodologies would greatly benefit bioanalytical labs in several aspects, including cost saving, method development and validation, and GLP compliance.

What will you learn?

  • Bioanaytical quantitation of proteins
  • Orthogonal options in bioanalytical quantitation
  • Comparison of HRMS and QTRAP

Who should attend?

  • Bioanalytical Scientists
  • Laboratory Managers/Group Leaders/Sr Scientists
  • Bioanalytical Laboratory Directors
January 27, 2015
7:00 a.m. PST
10:00 a.m. EST
15:00 GMT
Mingshe Zhu, P.h.D.
Principal Scientist, Biotransformation
Pharmaceutical Candidate Optimization
Bristol-Myers Squibb

 

We use cookies and by using this site or closing this message, you agree to our privacy policy.
Accept Cookies
×

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.
Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.
© 2020 DH Tech. Dev. Pte. Ltd.